ClinicalTrials.gg
CompletedNCT01911442Updated Feb 25, 2016Results posted

Lurasidone Pediatric Autism Study

A Phase 3 interventional study of Lurasidone 20 mg daily and Lurasidone in Autism, sponsored by Sumitomo Pharma America, Inc.. Completed at 41 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-02-25.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
70th of 504
150 · median 44
Started
2013
with 29 others
Phase 3
29 of 603
1 open now
Registered
227th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 70th largest by enrollment of the 504 interventional ones that give a count, is one of 30 that started in 2013, is one of 29 in phase 3, and was the 227th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.

03

Conditions studied

  • Autism

Browse trials for

Keywords

  • Autism, Lurasidone, Latuda
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.
  • Male or female subjects 6 to 17 years of age, inclusive, at the time of consent.
  • A reliable informant (eg, parent, legal guardian, or caregiver) who has past and current direct knowledge of the subject must accompany the subject at each visit and must oversee the administration of the study drug.
  • primary diagnosis of autistic disorder confirmation of the diagnosis by a trained clinician (eg, psychiatrist, psychologist, social workers, etc) at the time of screening, by means of the Autism Diagnostic Interview, Revised (ADI-R).
  • Screening and Baseline ABC irritability subscale score ≥ 18.
  • Screening and Baseline CGI-S ≥ 4.
  • Within 5th to 95th percentile for gender specific Growth Charts from Centers for Disease Control (CDC).
  • No abnormal laboratory values.
  • No clinically relevant abnormal vital sign values/findings

    1. Females who participate in this study:

      • are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
      • practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken;

-OR-

•are sexually active and willing to use a medically effective method of (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

  • Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
  • In the judgment of the investigator, the subject is able to swallow the size and number of study drug tablets specified per protocol (See Table 4 for study drug tablet size).
  • Able to adhere to protocol-specified meal requirements during dosing.
  • Have a stable living arrangement for at least 3 months prior to screening.
  • Non-pharmacologic therapy (eg, behavior modification) must be stable for at least 4 weeks before screening and consistent throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with profound intellectual disability.
  • Current diagnosis of bipolar disorder, psychosis, schizophrenia or major depression, or childhood disintegrative disorder as confirmed by the MINI-Kid (as appropriate) at screening. Confirmed genetic disorders with cognitive and behavioral disturbances are also exclusionary.
  • neurological, metabolic (including type 1 and type 2 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.

Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during screening.

  • Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood- eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.
  • If the subject has a history of seizures, the subjects must not currently be taking any antiepileptic drugs (AEDs) and be seizure-free for at least 6 months.
  • Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
  • A history or presence of abnormal , which in the investigator's opinion is clinically significant. Screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
  • Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes, severe dystonia, or moderate to severe tardive dyskinesia.
  • Clinically significant alcohol abuse/dependence or drug abuse/dependence based on Mini International Neuropsychiatric Interview for children and adolescents (MINI-Kid) criteria within the last 6 months prior to screening.
  • Clinically significant orthostatic hypotension (ie, a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 4 minutes of standing up).
  • Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
  • Positive test results at screening for:

    1. Urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, cannabinoids, methamphetamine, and methadone). However, a positive test for amphetamines, barbiturates, opiates, benzodiazepines or methadone may not result in exclusion of subjects if the investigator determines that the positive test is as a result of prescription medicine(s).
    2. Pregnancy test (only in female subjects ≥ 11 years old).
  • Lifetime history of (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of or C.
  • Participated in another interventional clinical trial or receiving an product within 30 days prior to study drug administration.
  • Use of concomitant medications that consistently prolong the /QTc interval within 28 days prior to randomization.
  • Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to screening, whichever is longer.
  • Subject has received treatment with antidepressants within 3 days, fluoxetine hydrochloride at any time within 21 days, an MAO inhibitor within 21 days of randomization or clozapine within 120 days of randomization. Depot neuroleptics must be discontinued at least one treatment cycle prior to randomization.
  • Use of any antipsychotic medication (other than study drug), carbamazepine, oxcarbazepine or fluvoxamine, within 3 days prior to randomization.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Donation of whole blood within 60 days prior to randomization.
  • Has a prolactin concentration greater than or equal to 100 ng/mL at screening.
  • Subject is considered by the investigator to be at imminent risk of suicide during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 12 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
  • Clinically relevant history of drug to lurasidone or any components in the formulation.
  • Subject requires use of concomitant medications that are potent inducers or inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system (Appendix C) from signing until follow-up.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Lurasidone 20 mg

    Lurasidone 20 mg once daily

    Drug: Lurasidone 20 mg daily

  • Experimental
    Lurasidone 60 mg

    Lurasidone 60 mg once daily

    Drug: Lurasidone

  • Placebo comparator
    Placebo

    Placebo once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6

    The ABC irritability subscale score is the sum of 15 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC irritability subscale score ranges from 0 to 45. Higher values of ABC subscale scores represent greater severity of illness.

    Time frame: Baseline to 6 Weeks

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6

    The Clinical Global Impression - Severity of Illness (CGI-S) Scale is rated on a 7-point scale of severity with 1 = Normal, not at all ill to 7 = Among the most extremely ill patients. Higher values of CGI-S scores represent greater severity of illness.

    Time frame: Baseline to 6 Weeks

  2. Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6

    The ABC hyperactivity and noncompliance subscale score is the sum of 16 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC hyperactivity and noncompliance subscale score may range from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness.

    Time frame: Baseline to 6 Weeks

  3. Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)

    CY-BOCS total score ranges from 0 to 20. The higher value of CY-BOCS scores the greater severity of illness. This table is a summary of Y-BOCS compulsion total score.

    Time frame: 6 Weeks

  4. Change From Baseline in the Caregiver Strain Questionnaire (CGSQ)

    CGSQ is a caregiver reported assessment to assesses extent to which caregivers are affected by special demands associated with caring for a child with emotional/behavioral problems. CGSQ is comprised of three subscales which range in severity from 1 to 5 (Objective Strain, Subjective Externalized Strain, Subjective Internalized Strain), The 3 subscales are calculated as the averages of the corresponding individual items. Higher scores on each indicates greater strain. A Global Strain score is calculated by summing the three subscales (Objective Strain, Subjective Externalized Strain, Subjective Internalized Strain) to provide an indication of the total impact of the special demands on the family. Global Strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain.

    Time frame: 6 Weeks

  5. Proportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6

    Time frame: 6 Weeks

  6. Proportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.

    Time frame: 6 Weeks

07

Results

Posted Feb 25, 2016

Participant flow

Participants were recruited from 46 centers in the United States between August 2013 and October 2014

Participant flow — Overall Study
MilestoneLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Started495150
Completed434738
Not completed6412
Withdrew: Adverse event224
Withdrew: Lack of efficacy111
Withdrew: Lost to follow-up201
Withdrew: Withdrawal by subject106
Withdrew: Mother's work schedule010

Outcome measures

PrimaryChange in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6

The ABC irritability subscale score is the sum of 15 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC irritability subscale score ranges from 0 to 45. Higher values of ABC subscale scores represent greater severity of illness.

Time frame:
Baseline to 6 Weeks
Reported as:
Least squares mean · units on a scale
Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6
units on a scaleLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 68.8 ± 1.59.4 ± 1.437.5 ± 1.52
Statistical analysis
  • Lurasidone 20 mg Once Daily vs Placebo · Mixed Models Analysis · p = 0.5463 · Mean difference (final values): -1.3 · 95% CI -5.6 to 3.0
  • Lurasidone 60 mg Once Daily vs Placebo · Mixed Models Analysis · p = 0.3592 · Mean difference (final values): -1.9 · 95% CI -6.1 to 2.2
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6

The Clinical Global Impression - Severity of Illness (CGI-S) Scale is rated on a 7-point scale of severity with 1 = Normal, not at all ill to 7 = Among the most extremely ill patients. Higher values of CGI-S scores represent greater severity of illness.

Time frame:
Baseline to 6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6
units on a scaleLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Change From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 6-1.1 ± 0.17-1.0 ± 0.16-0.7 ± 0.17
Statistical analysis
  • Lurasidone 20 mg Once Daily vs Placebo · Mixed Models Analysis · p = 0.1755 · Mean difference (final values): -0.3This is due to rounding. the LSM for Lurasidone 20 mg/d at week 6 was -1.069 vs -0.734 for placebo group. So the LSM of the treatment difference between Lurasidone 20 mg/d and placebo was 0.335 if 3 decimals are reported.
  • Lurasidone 60 mg Once Daily vs Placebo · Mixed Models Analysis · p = 0.2402 · Mean difference (final values): -0.3
SecondaryChange From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6

The ABC hyperactivity and noncompliance subscale score is the sum of 16 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC hyperactivity and noncompliance subscale score may range from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness.

Time frame:
Baseline to 6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6
units on a scaleLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score at Week 6-9.7 ± 1.50-6.6 ± 1.43-7.1 ± 1.52
SecondaryChange From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)

CY-BOCS total score ranges from 0 to 20. The higher value of CY-BOCS scores the greater severity of illness. This table is a summary of Y-BOCS compulsion total score.

Time frame:
6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)
units on a scaleLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scales (CY-BOCS) Modified for Pervasive Developmental Disorders (PDDs)-1.0 ± 0.46-1.0 ± 0.44-1.2 ± 0.49
SecondaryChange From Baseline in the Caregiver Strain Questionnaire (CGSQ)

CGSQ is a caregiver reported assessment to assesses extent to which caregivers are affected by special demands associated with caring for a child with emotional/behavioral problems. CGSQ is comprised of three subscales which range in severity from 1 to 5 (Objective Strain, Subjective Externalized Strain, Subjective Internalized Strain), The 3 subscales are calculated as the averages of the corresponding individual items. Higher scores on each indicates greater strain. A Global Strain score is calculated by summing the three subscales (Objective Strain, Subjective Externalized Strain, Subjective Internalized Strain) to provide an indication of the total impact of the special demands on the family. Global Strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain.

Time frame:
6 Weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Caregiver Strain Questionnaire (CGSQ)
units on a scaleLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Change From Baseline in the Caregiver Strain Questionnaire (CGSQ)-1.49 ± 0.292-1.66 ± 0.274-1.35 ± 0.300
SecondaryProportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6
Time frame:
6 Weeks
Reported as:
Number · percentage of subjects
Proportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6
percentage of subjectsLurasidone 20 mgLurasidone 60 mgPlacebo
Proportion of Subjects Who Have CGI-I Score of 1 (Very Much Improved) or 2 (Much Improved) at Week 6171714
SecondaryProportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.
Time frame:
6 Weeks
Reported as:
Number · percentage of subjects
Proportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.
percentage of subjectsLurasidone 20 mgLurasidone 60 mgPlacebo
Proportion of Subjects Who Have at Least 25% Reduction From Baseline to Week 6 in the ABC Irritability Subscale Score.252623

Adverse events

Collected over Adverse event data were collected as spontaneous reports at all visits. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone 20 mg Once Daily—3/49 (6.1%)33/49 (67.3%)
Lurasidone 60 mg Once Daily—2/51 (3.9%)38/51 (74.5%)
Placebo—0/49 (0%)28/49 (57.1%)
Most frequent serious events
Most frequent serious events
EventLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
Torus FractureInjury, poisoning and procedural complications1/491/510/49
Upper Limb FractureInjury, poisoning and procedural complications1/491/510/49
IrritabilityGeneral disorders1/490/510/49
AppendicitisGeneral disorders0/491/510/49
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlacebo
VomitingGastrointestinal disorders4/4914/512/49
SomnolenceNervous system disorders3/499/512/49
NasopharynigitisInfections and infestations5/493/510/49
InsomniaPsychiatric disorders1/491/515/49
DiarrhoeaGastrointestinal disorders1/494/514/49
FatigueGeneral disorders1/494/511/49
Weight IncreasedInvestigations1/494/511/49
AkathisiaNervous system disorders3/493/510/49
HeadacheNervous system disorders2/493/513/49
SedationNervous system disorders3/491/511/49

Baseline characteristics

The disposition table for the overall study used all subjects randomized. The baseline characteristics summary used safety population. 1 subject in placebo group did not take any study medication, and was removed from the safety population.

Age, Categorical
Age, Categorical(Participants)Lurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlaceboTotal
<=18 years495149149
Between 18 and 65 years0000
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlaceboTotal
Female108927
Male394340122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlaceboTotal
Hispanic or Latino117725
Not Hispanic or Latino384442124
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlaceboTotal
American Indian or Alaska Native1102
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American109524
White353842115
More than one race0112
Unknown or Not Reported3104
Region of Enrollment
Region of Enrollment(participants)Lurasidone 20 mg Once DailyLurasidone 60 mg Once DailyPlaceboTotal
United States495149149
08

Study locations

41 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • Southwest Autism Research & Resource Center
    Phoenix, Arizona 85006, United States
  • Newport Beach Clinical Research Associates
    Newport Beach, California 92663, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • Sarkis Clinical Trials - Parent
    Gainesville, Florida 32607, United States
  • Palm Springs Research Institute Inc
    Hialeah, Florida 33012, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Medical Research Group of Central Florida
    Sanford, Florida 32771, United States
  • University of South Florida
    St. Petersburg, Florida 33701, United States
  • University of South Florida
    Tampa, Florida 33613-4706, United States
  • Institute for Behavioral Medicine, LLC
    Smyrna, Georgia 30080, United States
  • Capstone Clinical Research, Inc.
    Libertyville, Illinois 60048, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • University of Kentucky
    Lexington, Kentucky 40509, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70629, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21287, United States
  • NeuroScientific Insights
    Rockville, Maryland 20852, United States
  • Neurobehaviorial Medicine Group, PLLC
    Bloomfield Hills, Michigan 48302, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Jersey Shore University Medical Center
    Neptune City, New Jersey 07753, United States
  • Childrens Specialized Hospital
    Toms River, New Jersey 08755, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Montefiore Medical Center PRIME
    The Bronx, New York 10467, United States
  • Chapel Hill Neurology
    Chapel Hill, North Carolina 27517, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Nisonger Center
    Columbus, Ohio 43210, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Cyn3rgy Research & Development
    Gresham, Oregon 97030, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Segal Institute for Clinical Research
    Charleston, South Carolina 29407, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Family Psychiatry of The Woodlands, P.A.
    The Woodlands, Texas 77381, United States
  • Ericksen Research & Development, LLC
    Clinton, Utah 84015, United States
  • CRI Lifetree
    Salt Lake City, Utah 84106, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Neuroscience, Inc.
    Herndon, Virginia 20170, United States
  • Carilion Clinic
    Roanake, Virginia 24014, United States
  • Pacific Institute of Medical Sciences
    Bothell, Washington 98011, United States
09

References and documents

Publications

  • Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2. PubMed 37811711 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Jul 30, 2013
Start
Aug 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Feb 25, 2016
Last update
Feb 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01911442
Responsible party
Sponsor
First posted
Jul 30, 2013
Start date
Aug 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Feb 25, 2016
Last update
Feb 25, 2016

Study contacts

Lurasidone Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion